Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?

Rezaee Michael E.; Gross Martin S.

首页> 外文期刊>The journal of sexual medicine >Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?

【24h】

Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?

机译：我们是否夸大了口服磷酸二酯酶5型抑制剂的Priapism的风险？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Priapism is an adverse drug reaction (ADR) associated with phosphodiesterase type 5 inhibitors (PDE5is) in the treatment of erectile dysfunction.

机译：背景：阴茎异常勃起是一种与磷酸二酯酶5型抑制剂（PDE5is）治疗勃起功能障碍相关的不良药物反应（ADR）。

著录项

来源
《The journal of sexual medicine》 |2020年第8期|共4页
作者
Rezaee Michael E.; Gross Martin S.;
展开▼
作者单位

Dartmouth Hitchcock Med Ctr Dept Surg Urol Sect One Med Ctr Dr Lebanon NH 03756 USA;

Dartmouth Hitchcock Med Ctr Dept Surg Urol Sect One Med Ctr Dr Lebanon NH 03756 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类性卫生;
关键词
Erectile Dysfunction; Priapism; PDE5 Inhibitors; Men's Health;

机译：勃起功能障碍;pde5抑制剂;男人的健康;

相似文献

外文文献
中文文献
专利

1. A meta-regression evaluating the effectiveness and prognostic factors of oral phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction [J] . Jin-Qiu Yuan, Chen Mao, Zu-Yao Yang, 亚洲男性学杂志（英文版） . 2016,第001期
2. The effects of single versus combined therapy using LIM-kinase 2 inhibitor and type 5 phosphodiesterase inhibitor on erectile function in a rat model of cavernous nerve injury-induced erectile dysfunction [J] . Min Chul Cho, Junghoon Lee, Juhyun Park, 亚洲男性学杂志（英文版） . 2019,第005期
3. Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension [J] . Yuncong Yang, Yi-You Huang, Lei Guo, 药学学报（英文版） . 2020,第012期
4. Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension [J] . Yuncong Yangy, Sirui Zhangy, Qian Zhouy, 药学学报：英文版 . 2020,第012期
5. Oral Phosphodiesterase Type 5 Inhibitors in Recurrent Priapism Complicating Thalassemia Intermedia: A Case Report [J] . Davood Maleki Case Reports in Clinical Medicine . 2014,第6期

机译：复发性轻瘫并发地中海贫血症的口服磷酸二酯酶5型抑制剂：病例报告
6. Oral phosphodiesterase type 5 inhibitors alleviate recurrent priapism complicating thalassemia intermedia: a case report. [J] . Tzortzis V, Mitrakas L, Gravas S, The journal of sexual medicine . 2009,第7期

机译：口服磷酸二酯酶5型抑制剂可缓解复发性阴茎异常勃起并发中地中海贫血：一例病例。
7. Risk-benefit assessment of oral phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction: a multiple criteria decision analysis [J] . Hsu J. C., Tang D. H., Lu C. Y. International journal of clinical practice . 2015,第4期

机译：口服磷酸二酯酶5型抑制剂治疗勃起功能障碍的风险效益评估：多标准决策分析
8. Analysis of Phosphodiesterase Type 5 Inhibitors Extracted from Herbal Preparations by DSA-TOF MS [C] . Robert J. Seward, Jason Weisenseel, Craig Young, ASMS Conference on Mass Spectrometry and Allied Topics . 2016

机译：DSA-TOF MS从草药制剂中提取的磷酸二酯酶型5抑制剂的分析
9. Lessons learned in the synthesis of a diversity-oriented library of phosphodiesterase inhibitors. [D] . Brady, Bernard Francis. 2013

机译：在磷酸二酯酶抑制剂多样性导向文库合成中获得的经验教训。
10. Combination phosphodiesterase type 4 inhibitor and phosphodiesterase type 5 inhibitor treatment reduces non-voiding contraction in a rat model of overactive bladder [O] . Brian M. Balog, Abhilasha Tangada, Pooja Sheth, 2012

机译：磷酸二酯酶4型抑制剂和磷酸二酯酶5型抑制剂的组合治疗可减轻膀胱过度活动症大鼠模型中的非空洞收缩
11. PCV65 Quantitative risk-benefit analysis of oral phosphodiesterase type 5 inhibitors on erectile dysfunction treatment [O] . Hsu J.C., Tang D. 2013

机译：PCV65口服磷酸二酯酶5型抑制剂对勃起功能障碍治疗的定量风险效益分析
12. Investigation of a Putative Estrogen-Imprinting Gene, Phosphodiesterase Type IV Variant (Pde4d4), in Determining Prostate Cancer Risk; Final rept. 15 Mar 2006-14 Mar 2008 [R] . Tang, W. 2008

机译：研究推定的雌激素印迹基因，磷酸二酯酶IV型变异体（pde4d4），用于确定前列腺癌风险;最终的评论。 2006年3月15日至2008年3月14日

Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors?

摘要

著录项

相似文献

相关主题

期刊订阅